Experimental chemotherapy for Chagas disease: 15 years of researchcontributions from in vivo and in vitro studies
2009
Chagas disease, which is caused by the intracellular parasite
Trypanosoma cruzi , is a neglected illness with 12-14 million reported
cases in endemic geographic regions of Latin America. While the disease
still represents an important public health problem in these affected
areas, the available therapy, which was introduced more than four
decades ago, is far from ideal due to its substantial toxicity, its
limited effects on different parasite stocks, and its poor activity
during the chronic phase of the disease. For the past 15 years, our
group, in collaboration with research groups focused on medicinal
chemistry, has been working on experimental chemotherapies for Chagas
disease, investigating the biological activity, toxicity, selectivity
and cellular targets of different classes of compounds on T. cruzi. In
this report, we present an overview of these in vitro and in vivo
studies, focusing on the most promising classes of compounds with the
aim of contributing to the current knowledge of the treatment of Chagas
disease and aiding in the development of a new arsenal of candidates
with anti-T. cruzi efficacy.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI